Journal article

Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology

John Heymach, Lada Krilov, Anthony Alberg, Nancy Baxter, Susan Marina Chang, Ryan Corcoran, William Dale, Angela DeMichele, Catherine S Magid Diefenbach, Robert Dreicer, Andrew S Epstein, Maura L Gillison, David L Graham, Joshua Jones, Andrew H Ko, Ana Maria Lopez, Robert G Maki, Carlos Rodriguez-Galindo, Richard L Schilsky, Mario Sznol Show all

Journal of Clinical Oncology | AMER SOC CLINICAL ONCOLOGY | Published : 2018

Grants

Funding Acknowledgements

John Heymach Research Funding: AstraZeneca (Inst)Susan Marina Chang Research Funding: Novartis (Inst), Quest Diagnostics (Inst), Agios (Inst), Roche (Inst)Ryan Corcoran Research Funding: AstraZeneca, SanofiAngela DeMichele Research Funding: Pfizer (Inst), Genentech (Inst), Incyte (Inst), Millennium Pharmaceuticals (Inst), Bayer (Inst), Veridex (Inst), Calithera Biosciences (Inst), GlaxoSmithKline (Inst), Wyeth (Inst)Catherine S. Magid Diefenbach Research Funding: Seattle Genetics (Inst), Genentech (Inst), Merck (Inst), LAM Therapeutics (Inst), Takeda Pharmaceuticals (Inst), Incyte (Inst), Bristol-Myers Squibb (Inst)Maura L. Gillison Research Funding: Bristol-Myers Squibb (Inst), AstraZeneca (Inst), Merck (Inst)Andrew H. Ko Research Funding: PRISM BioLab (Inst), Celgene (Inst), Aduro Biotech (Inst), Merck (Inst), Merrimack Pharmaceuticals (Inst), Acerta Pharma (Inst), Genentech (Inst), Bristol-Myers Squibb (Inst), Halozyme (Inst), AbGenomics International (Inst), Apexigen (Inst)Robert G. Maki Research Funding: TRACON Pharma (Inst), Immune Design (Inst), Eli Lilly (Inst), Regeneron (Inst)Richard L. Schilsky Research Funding: AstraZeneca (Inst), Bayer (Inst), Bristol-Myers Squibb (Inst), Genentech (Inst), Eli Lilly (Inst), Merck (Inst), Pfizer (Inst)Shannon Neville Westin Research Funding: AstraZeneca, Novartis, Merck, Biomarin, GlaxoSmithKline, Karyopharm Therapeutics (I), Celgene (I), Critical Outcome Technologies, Bayer, Tesaro, Kite Pharma (I)